EMSP launched the European Register for Multiple Sclerosis (EUReMS) with the support and co-financing of the European Commission, under the Public Health Programme:

Call 2010, Priority area: 3.3.2 Promote health – Promote healthier ways of life and reduce major diseases and rare diseases – Subaction: Neurodegenerative diseases-launch first phase of multiple sclerosis

Duration: 36 months
Start date: 1 July 2011
Total budget: EUR 1.646.503,00
EC Contribution: EUR 987.198,00

The content of this website reflects only the author's views and the Commission cannot be held responsible for any use which may be made of the information contained therein.

The EUReMS project is supported by the following sponsors: Almirall, Bayer Pharma AG, Biogen Idec, GSK, Roche,  Genzyme, Medtronic Foundation, Merck Serono, Coloplast, Novartis, TEVA, GW pharmaceuticals. 

As an independant non-profit organisation, the European Multiple Sclerosis Platform's relationship with pharmaceutical industry complies to the rules of a Code of conduct which ensures its independance and transparency.